Shay Capital’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Shay Capital’s Portfolio IRLA Stock Details IRLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$329K	Buy	17,468 +8,603	+97%	+$198K	0.02%	348
2026 Q1	$180K	Buy	+8,865	New	+$1.78M	0.02%	397
2025 Q4	–	Sell	-685	Closed	-$223K	–	588
2025 Q3	$223K	Sell	685 -65	-9%	-$21.6K	0.02%	344
2025 Q2	$248K	Sell	750 -172	-19%	-$39.3K	0.03%	240
2025 Q1	$245K	Sell	922 -462	-33%	-$141K	0.04%	219
2024 Q4	$518K	Buy	1,384 +523	+61%	+$157K	0.08%	176
2024 Q3	$134K	Buy	+861	New	+$123K	0.02%	267

Other funds holding IRLA

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Shay Capital's IRLA Position: Q2 2026 in Review

Shay Capital increased its IRulya Therapeutics Inc. Common Stock (IRLA) stake by 97% in Q2 2026, buying an estimated $198K and bringing the position to 17,468 shares worth $329K. The position accounts for 0.02% of the portfolio, ranked #348.

Shay Capital first reported a position in IRLA in Q3 2024 and has held it in 7 quarters since. The position peaked at $518K in Q4 2024. 26 funds tracked by Wall St. Rank hold IRLA as of Q2 2026.

Shay Capital held 17,468 shares of IRulya Therapeutics Inc. Common Stock worth $329K as of Q2 2026.
Shay Capital bought 8,603 IRulya Therapeutics Inc. Common Stock shares in Q2 2026, an estimated $198K.
IRulya Therapeutics Inc. Common Stock made up 0.02% of Shay Capital's portfolio in Q2 2026, its #348 holding.
Shay Capital first reported a position in IRulya Therapeutics Inc. Common Stock in Q3 2024 and has held it in 7 quarters since.
Shay Capital's IRulya Therapeutics Inc. Common Stock position peaked at $518K in Q4 2024.
26 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2026.

Based on Shay Capital's 13F filing for Q2 2026, filed 14 Aug 2026.